Royalty Pharma plc (RPRX) Earnings History
Steady Earner9 years of earnings data (2017–2025) · Positive but moderate multi-year EPS trajectory
Loading earnings history...
Royalty Pharma plc (RPRX) Earnings Overview
As of June 23, 2026, Royalty Pharma plc (RPRX) reported trailing twelve-month net income of $828M, reflecting -5.8% year-over-year growth. The company earned $1.48 per diluted share over the past four quarters, with a net profit margin of 32.4%.
Looking at the long-term picture, RPRX's 5-year EPS compound annual growth rate (CAGR) stands at +7.1%, showing solid earnings momentum. The company achieved its highest annual net income of $2.35B in fiscal 2019.
Royalty Pharma plc maintains industry-leading profitability with a gross margin of 100.0%, operating margin of 65.6%, and net margin of 32.4%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including RCUS (-$369M net income, -142.9% margin), OR ($254M net income, 74.3% margin), WPM ($1.80B net income, 63.6% margin), RPRX has outperformed on profitability metrics. Compare RPRX vs RCUS →
RPRX Earnings vs Peers
Earnings metrics vs comparable public companies
RPRX Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $771M | -10.2% | $1.56B | $1.80 | 32.4% | 65.6% |
| 2024 | $859M | -24.3% | $1.29B | $1.91 | 37.9% | 57.1% |
| 2023 | $1.13B | +2549.5% | $1.49B | $2.53 | 48.2% | 63.4% |
| 2022 | $43M | -93.1% | $307M | $0.10 | 1.9% | 13.7% |
| 2021 | $620M | -36.4% | $1.43B | $1.49 | 27.1% | 62.5% |
| 2020 | $975M | -58.5% | $1.60B | $1.28 | 45.9% | 75.2% |
| 2019 | $2.35B | +70.5% | $2.62B | $6.63 | 129.4% | 144.6% |
| 2018 | $1.38B | +13.9% | $1.36B | $3.89 | 76.8% | 76.0% |
| 2017 | $1.21B | - | $940M | $3.42 | 75.7% | 58.8% |
Download Data
Export RPRX earnings history in CSV or JSON format
Free sign-in required to download data
Full Stock Analysis
Deep dive into RPRX consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
RPRX — Frequently Asked Questions
Quick answers to the most common questions about buying RPRX stock.
What is RPRX earnings per share (EPS)?
RPRX trailing twelve-month (TTM) diluted EPS is $1.48, reflecting -5.8% year-over-year growth. The 5-year EPS CAGR is +7.1%. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is Royalty Pharma plc's net income?
Royalty Pharma plc (RPRX) trailing twelve-month net income is $828M as of 2025. Earnings declined -5.8% year-over-year. Royalty Pharma plc has been profitable for 9 consecutive years.
Is RPRX profitable?
Yes, RPRX is profitable with a TTM net income of $828M and a net profit margin of +32.4%. Royalty Pharma plc has generated profits for 9 consecutive years.
What is RPRX's earnings growth rate?
RPRX compound annual EPS growth rates (CAGR): 1-Year: -5.8%, 3-Year: +162.1%, 5-Year: +7.1%, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are RPRX's profit margins?
Royalty Pharma plc net profit margin is +32.4%, operating margin is +65.6%, and gross margin is +100.0%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +7.7%.
Is RPRX growing earnings?
RPRX earnings are declining — EPS fell -5.8% year-over-year. TTM net income dropped to $828M. This contrasts with the 5-year CAGR of +7.1%.
What was RPRX's best earnings year?
Royalty Pharma plc's highest annual net income on record is $2.3B, achieved in fiscal year 2019. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were RPRX's earnings last quarter?
RPRX's most recent reported quarter was Q1 2026. Net income was $295M with diluted EPS of $0.53. For a full breakdown of all quarters, see the quarterly earnings table on this page.